Drug Type Synthetic peptide |
Synonyms ASCT 1003, ASCT1003 |
Target |
Action inhibitors |
Mechanism BTRC inhibitors(beta-transducin repeat containing E3 ubiquitin protein ligase inhibitors), REST inhibitors(RE1 silencing transcription factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Preclinical | United States | 01 Feb 2026 | |
| Breast Cancer | Preclinical | United States | 01 Feb 2026 | |
| Colonic Cancer | Preclinical | United States | 01 Feb 2026 | |
| Parkinson Disease | Preclinical | United States | 01 Feb 2026 |






